MS

:   mass spectrometry

OSCC

:   oral squamous cell carcinoma

UPLC

:   ultraperformance liquid chromatography

The oral cavity is the most frequent site of head and neck cancers, developing predominantly as oral cavity squamous cell carcinomas (OSCCs) in the upper aerodigestive epithelium [1](#feb412391-bib-0001){ref-type="ref"}, [2](#feb412391-bib-0002){ref-type="ref"}. The three major recognized risk factors of OSCC are tobacco consumption, alcohol consumption, and poor oral hygiene [3](#feb412391-bib-0003){ref-type="ref"}, [4](#feb412391-bib-0004){ref-type="ref"}, [5](#feb412391-bib-0005){ref-type="ref"}. OSCC mortality rates reflect the different consumption patterns of alcohol and tobacco in European countries [6](#feb412391-bib-0006){ref-type="ref"}. Annually, more than 300 000 new patients are diagnosed with OSCC worldwide. The disease is associated with poor prognosis and high mortality mainly due to late diagnosis because of the lack of reliable early diagnostic markers [7](#feb412391-bib-0007){ref-type="ref"}. Mortality rate from OSCC is about 10‐fold higher for men than for women. However, female OSCC incidence increased dramatically in the last decade. In addition, a rising tendency was observed in younger patient cohorts [8](#feb412391-bib-0008){ref-type="ref"}. In contrast to other European countries where the mortality rates of OSCC started to decline, unfavorable incidence and mortality figures remained exceedingly high in Hungary since the 1970s representing a major public health challenge [9](#feb412391-bib-0009){ref-type="ref"}.

Development of cancer diagnostic tools with sufficiently high sensitivity and specificity is required to enable early detection of OSCC [10](#feb412391-bib-0010){ref-type="ref"}. Recent treatment strategies of patients with OSCC are based on traditional stage‐predicting indices and histological grading [11](#feb412391-bib-0011){ref-type="ref"}. Unfortunately, these predictors are relatively subjective and unreliable because tumors with the same staging and grading may respond to therapy differently. Thus, improving the diagnostic methods is required. A potential way of improving our diagnostic tools is to perform in‐depth salivary analyses to discover and to assess biochemical and immunological markers in the saliva for early oral cancer diagnosis [12](#feb412391-bib-0012){ref-type="ref"}, [13](#feb412391-bib-0013){ref-type="ref"}. Biomarkers identified in the last decades in biological fluids can be linked to carcinogenesis and may serve as prognostic factors and saliva is a new clinical biomarker source that can be easily collected by noninvasive means [14](#feb412391-bib-0014){ref-type="ref"}, [15](#feb412391-bib-0015){ref-type="ref"}, [16](#feb412391-bib-0016){ref-type="ref"}, [17](#feb412391-bib-0017){ref-type="ref"}, [18](#feb412391-bib-0018){ref-type="ref"}. As there is direct contact between saliva and the oral lesion(s), disease‐related concentration changes of saliva ingredients may provide as good or better clues than serum samples [19](#feb412391-bib-0019){ref-type="ref"}. More than 3700 salivary proteins have been identified by several research groups [20](#feb412391-bib-0020){ref-type="ref"}, [21](#feb412391-bib-0021){ref-type="ref"}. Many proteins were declared potential salivary biomarkers of OSCC in different countries [22](#feb412391-bib-0022){ref-type="ref"}, [23](#feb412391-bib-0023){ref-type="ref"}, [24](#feb412391-bib-0024){ref-type="ref"}. In this study, we present a two‐stage approach for the discovery of candidate OSCC‐specific salivary biomarkers in the Hungarian population. LC‐mass spectrometry (MS)/MS analysis using ultraperformance liquid chromatography (UPLC) coupled to a linear ion trap‐Orbitrap hybrid tandem mass spectrometer was applied for qualitative and quantitative salivary protein profiling. Selected proteins, based on the shotgun analysis of a few randomly selected samples, were further investigated by ELISA on a reference set of samples.

Materials and methods {#feb412391-sec-0002}
=====================

Patients and saliva collection {#feb412391-sec-0003}
------------------------------

Donor enrollment, sample collection, and processing conformed to the principles of the Helsinki Declaration. Ethical approval was obtained from the University of Debrecen Ethics Committee (No. 3385‐2011), and all subjects provided written informed consent. Clinical examinations were performed by dental surgeons from the Faculty of Dentistry, University of Debrecen. Adult patients (\> 18 years) with histology‐proven OSCC were recruited into the study. Saliva samples were collected before starting any antitumor therapy. Age‐matched controls (MCTL) were consecutive patients and young controls (YCTL) were medical students admitted to the Faculty of Dentistry for regular dental checkup. Exclusion criteria included children (≤ 18 years), pregnancy and breast‐feeding, diabetes mellitus, human papillomavirus infection, human immunodeficiency virus infection, autoimmune and immunodeficiency disorders, and cancer other than OSCC.

Unstimulated saliva samples were collected from 43 donors between 9 a.m. and 11 a.m. at the Faculty of Dentistry, University of Debrecen (collection between May 9, 2013, and February 29, 2016). The test set contained three randomly selected samples from patients with OSCC and controls for proteomics analysis, whereas the reference set contained samples from 20 patients with OSCC (mean age: 57 years), six YCTL (mean age: 24.5 years), and 11 MCTL (mean age: 59 years) for biomarker verification. Saliva samples were kept on ice during collection and were filtered using Millipore SLSV025LS 5‐μm‐pore‐size syringe filters (Merck, Billerica, MA, USA). The filtered saliva was aliquoted and immediately placed at −70 °C until further use.

Sample preparation for mass spectrometry {#feb412391-sec-0004}
----------------------------------------

Filtered saliva was dried in SpeedVac and redissolved in 25 m[m]{.smallcaps} pH 8.5 ammonium bicarbonate buffer. Total protein concentration of salivary samples was measured using the Bradford method [25](#feb412391-bib-0025){ref-type="ref"}. Following denaturation with 8 [m]{.smallcaps} urea, all samples were reduced with 10 m[m]{.smallcaps} dithiothreitol (Bio‐Rad, Hercules, CA, USA) in ammonium bicarbonate buffer. Then, samples were alkylated with 20 m[m]{.smallcaps} iodoacetamide (Bio‐Rad) in ammonium bicarbonate buffer and diluted with 25 m[m]{.smallcaps} ammonium bicarbonate (Sigma, St. Louis, MO, USA) to reduce the urea concentration to 1 [m]{.smallcaps}. Each sample was digested by MS‐grade modified trypsin (AB Sciex, Framingham, MA, USA) in 1 : 25 enzyme‐to‐protein ratio (w/w) at 37 °C overnight. The digested samples were dried in SpeedVac and redissolved in 0.1% formic acid. The digests were desalted on Pierce C18 Tips (Thermo Scientific, West Palm Beach, FL, USA), and the eluates were dried and stored at −70 °C until MS analysis.

Mass spectrometry analysis {#feb412391-sec-0005}
--------------------------

Tryptic digests representing 2 μg total protein were analyzed by LC‐MS/MS using a Waters nanoACQUITY UPLC Online coupled to a linear ion trap‐Orbitrap hybrid tandem mass spectrometer (Orbitrap Elite; Thermo Scientific) operating in positive ion mode. After trapping at 3% B (Waters Symmetry C18 180 μm × 20 mm column, 5 μm particle size, 100 Å pore size; flow rate: 10 μL·min^−1^), peptides were fractionated using a linear gradient of 3--40% B in 100 min (Waters BEH C18 75 μm × 250 mm column, 1.7 μm particle size, 300 Å pore size; solvent A: 0.1% formic acid/water; solvent B: 0.1% formic acid/5% dimethyl sulfoxide/acetonitrile; flow rate: 400 nL·min^−1^). Data acquisition was carried out in a data‐dependent fashion, and the 10 most abundant, multiply charged ions were selected from each MS survey (*m*/*z*: 380--1600; resolution: 60 000, acquired in profile mode) for MS/MS analyses. CID analyses were performed in the linear ion trap (normalized collision energy: 35). Dynamic exclusion was enabled (exclusion time: 30 s).

Protein identification {#feb412391-sec-0006}
----------------------

Peak lists generated from the MS/MS data by the '[pava]{.smallcaps}' software [26](#feb412391-bib-0026){ref-type="ref"} were searched against the human subset of the UniProt database (downloaded on June 10, 2014; 136 245 target sequences concatenated with a randomized sequence for each entry) using the [proteinprospector]{.smallcaps} search engine (v.5.10.9.). Search parameters: enzyme: trypsin with maximum 1 missed cleavage site; fixed modification: carbamidomethyl (Cys); variable modifications: acetylation (protein N terminus), oxidation (Met), and pyroglutamic acid formation (N‐terminal Gln) allowing up to two variable modifications per peptide; and mass accuracy: 5 p.p.m. and 0.6 Da for precursor and fragment ions (both monoisotopic), respectively. The following acceptance criteria were applied: score \> 22 and 15, and E‐value \< 0.01 and 0.05 for protein and peptide identifications, respectively. The false‐positive rates of the identified proteins and peptides were \< 1%. Relative abundance of individual proteins was estimated by spectral counting: The number of identifications per protein (PSMs) was normalized to the total number of identifications, and then, these relative spectral counts were compared across the different samples.

Functional analyses were performed in the case of proteins with at least three unique peptide identifications. For the calculation of the OSCC/control ratio, the proteins which were identified with at least three unique peptides in at least two of three samples in either the control or the OSCC group were considered.

Validation of the candidate biomarkers using ELISA {#feb412391-sec-0007}
--------------------------------------------------

All saliva samples from patients with OSCC and controls were analyzed in duplicate with quantitative ELISA. The ELISA kit for heparin cofactor 2 (Cat. number: LS‐F13221) was purchased from LifeSpan Biosciences (Seattle, WA, USA), for resistin (Cat. number: KHP0051) from Thermo Fisher Scientific (West Palm Beach, FL, USA), and for complement C5 (Cat. number: ab125963) from Abcam (Branford, CT, USA). The concentration of the studied proteins in saliva was measured by the sandwich ELISA method according to the instruction provided by the vendor of each kit. Absorbance was measured at 450 nm, and concentrations were calculated based on the recorded 7‐point calibration curves.

First, the variation coefficient of the parallel measurements was calculated and those data having more than 25 CV % value were excluded from statistical analysis.

Bioinformatics {#feb412391-sec-0008}
--------------

The cluster analysis was carried out with Cluster 3.0 (<http://cluster2.software.informer.com/>) using the [c clustering library]{.smallcaps} version 1.52, and the heat map was created with [java treeview]{.smallcaps} version 1.1.6r4 [27](#feb412391-bib-0027){ref-type="ref"}.

The protein--protein interaction network of salivary proteins was generated using [string]{.smallcaps} version 10.5 [28](#feb412391-bib-0028){ref-type="ref"}, [29](#feb412391-bib-0029){ref-type="ref"} applying default settings and medium stringency. After the generation of networks, the enriched gene ontology (GO) terms provided by the software were also examined.

The statistical analysis of ELISA data was performed using the Mann--Whitney *U*‐test and the two‐sample *t*‐test to compare the protein concentrations between groups. The data were considered significantly different where the *P* value was \< 0.05.

Results and Discussion {#feb412391-sec-0009}
======================

Demographic and clinical characteristics of patients with OSCC {#feb412391-sec-0010}
--------------------------------------------------------------

Among the included 17 patients, 13 were males and 4 females between the age of 44 and 73 years. The tumor developed in the tongue (T) in six cases and in the floor of the mouth (F) in four cases, and in three cases, it was detected in the gingival (G) region. In four cases, the tumor development showed multiple localization, and in two patients, the tumor developed in the T and either in the F or in the G region, while in another two patients, the tumor development was detected in the T, in the F, and also in the G region. Eight patients were discovered in early tumor development stage (stage I: 5; and stage II: 3), and nine patients were diagnosed with advanced tumors (stage III: 4; and stage IV: 5). There were six well‐differentiated (W), seven moderately differentiated (M), and four poorly differentiated (P) OSCC samples (Table [1](#feb412391-tbl-0001){ref-type="table-wrap"}).

###### 

Demographic and clinical characteristics of patients with OSCC. In the case of each patient, the gender, age, tumor localization, TNM classification, tumor stage, and stage of differentiation are given. M is for male and F for female. Regarding tumor localization, T is for tongue, G is for gingiva, and F is for floor of the mouth. The W is for well‐differentiated, M is for moderately differentiated, and P is for poorly differentiated tumors

  Patient code   Gender   Age (year)   Tumor localization   TNM classification   Tumor stage   Stage of differentiation
  -------------- -------- ------------ -------------------- -------------------- ------------- --------------------------
  1              M        73           T                    T2N1M0               III           W
  2              F        69           G                    T4N0M0               IV            W
  3              F        67           F                    T4N2M0               IV            W
  4              M        52           T; G; F              T4N1M0               IV            M
  5              M        57           T                    T3N0M0               III           W
  6              F        59           T                    T1N0M0               I             W
  7              M        67           F                    T1N0M0               I             W
  8              F        50           T                    T2N0M0               II            M
  9              M        52           T; G                 T2N2M0               IV            M
  10             M        48           T                    T1N0M0               I             M
  11             M        64           T                    T2N0M0               II            P
  12             M        44           G                    T4N1M0               IV            M
  13             M        44           T; F                 T3N0M0               III           M
  14             M        60           F                    T2N0M0               II            M
  15             M        49           T; G; F              T3N1M0               III           P
  16             M        47           G                    T1N0M0               I             P
  17             M        64           F                    T1N0M0               I             P
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Shotgun proteomics analysis of saliva samples {#feb412391-sec-0011}
---------------------------------------------

Three randomly selected samples from patients with OSCC and matched controls, respectively, were subjected to shotgun proteomics analysis. More than 500 proteins were identified from salivary samples. For protein quantification, spectral counting was used and the ratios of OSCC : CTL protein quantities have been determined. Detailed information of the identified proteins is presented in Table [S1](#feb412391-sup-0001){ref-type="supplementary-material"}.

The proteins with at least three unique sequences and with at least twofold change value (OSCC/CTL ratio \< 0.5 or \> 2) were subjected to further examination. A cluster analysis was carried out, and a heat map was generated to visualize the changes in protein amount in CTL and OSCC samples (Fig. [1](#feb412391-fig-0001){ref-type="fig"}). Based on cluster analysis, the protein levels can discriminate the OSCC group from the CTL group. Proteins were classified as salivary proteins or proteins being present in saliva under normal conditions and as acute‐phase proteins (Table [2](#feb412391-tbl-0002){ref-type="table-wrap"}). For protein classification, the UniProt and Sys‐BodyFluid databases were used; the latter contains more than 10 000 proteins of different body fluid proteomes [30](#feb412391-bib-0030){ref-type="ref"}. In addition, some proteins were classified as salivary proteins based on the literature data [21](#feb412391-bib-0021){ref-type="ref"}, [31](#feb412391-bib-0031){ref-type="ref"}, [32](#feb412391-bib-0032){ref-type="ref"}, [33](#feb412391-bib-0033){ref-type="ref"}, [34](#feb412391-bib-0034){ref-type="ref"}, [35](#feb412391-bib-0035){ref-type="ref"}.

![Cluster analysis and heat map of proteins identified in the CTL and OSCC groups. The relative peptide count (%), characteristic of each sample, is shown.](FEB4-8-556-g001){#feb412391-fig-0001}

###### 

List of proteins with at least twofold change between OSCC and CTL groups. The UniProt protein ID, the protein name, and function are presented. The representative identification and quantification data, the number (\#) of unique peptides, the sequence coverage (%Cov), and the OSCC/CTL ratio are given in each case. Classification indicating salivary (S) or acute‐phase (A) proteins is presented. The type of sample from patients with OSCC where the protein was identified is also listed. NI denotes proteins not identified in OSCC yet

  Protein ID         Protein name                                     \# Unique peptide   %Cov   OSCC/CTL ratio   Classification   Function                                         Type of OSCC sample
  ------------------ ------------------------------------------------ ------------------- ------ ---------------- ---------------- ------------------------------------------------ ---------------------------------------------------------------------------------------------
  [O60218](O60218)   Aldo‐keto reductase family 1 member B10          5                   17     0.10             S                Metabolic enzyme                                 Saliva[a](#feb412391-note-0002){ref-type="fn"} [23](#feb412391-bib-0023){ref-type="ref"}
  [P02763](P02763)   Alpha‐1‐acid glycoprotein 1                      8                   37     3.14             AS               Immune response, transport                       Saliva [16](#feb412391-bib-0016){ref-type="ref"}
  [P01011](P01011)   Alpha‐1‐antichymotrypsin                         12                  31     3.29             AS               Protease inhibitor                               NI
  [P01009](P01009)   Alpha‐1‐antitrypsin                              25                  62     3.70             S                Protease inhibitor                               Saliva [36](#feb412391-bib-0036){ref-type="ref"}
  [P04217](P04217)   Alpha‐1B‐glycoprotein                            12                  39     3.25             S                Immune response                                  Saliva [16](#feb412391-bib-0016){ref-type="ref"}
  [P02765](P02765)   Alpha‐2‐HS‐glycoprotein                          7                   26     2.70             AS               Protease inhibitor, immune response, transport   NI
  [P01023](P01023)   Alpha‐2‐macroglobulin                            54                  51     2.16             S                Protease inhibitor                               NI
  [P04745](P04745)   Alpha‐amylase 1                                  42                  83     0.21             S                Metabolic enzyme                                 Saliva [14](#feb412391-bib-0014){ref-type="ref"}
  [P01019](P01019)   Angiotensinogen                                  7                   18     8.50             AS               Renin--angiotensin system                        NI
  [P01008](P01008)   Antithrombin III                                 7                   22     2.08             AS               Protease inhibitor, blood coagulation            NI
  [P02647](P02647)   Apolipoprotein A‐I                               24                  69     2.14             S                Lipid metabolism                                 Saliva [23](#feb412391-bib-0023){ref-type="ref"}
  [P02652](P02652)   Apolipoprotein A‐II                              7                   67     3.85             S                Lipid metabolism                                 Saliva [23](#feb412391-bib-0023){ref-type="ref"}
  [P06727](P06727)   Apolipoprotein A‐IV                              5                   16     3.55             S                Lipid metabolism                                 Saliva [23](#feb412391-bib-0023){ref-type="ref"}
  [P04114](P04114)   Apolipoprotein B‐100                             42                  13     8.12             S                Lipid metabolism                                 NI
  [P02649](P02649)   APOE                                             4                   18     Only in OSCC     S                Lipid metabolism                                 Saliva [23](#feb412391-bib-0023){ref-type="ref"}
  [P17213](P17213)   Bactericidal permeability‐increasing protein     4                   12     0.24             S                Immune response                                  NI
  [P02749](P02749)   Beta‐2‐glycoprotein 1                            12                  44     3.02             S                Lipid metabolism, blood coagulation              Saliva [22](#feb412391-bib-0022){ref-type="ref"}
  [P61769](P61769)   Beta‐2‐microglobulin                             5                   57     0.46             S                Immune response                                  NI
  [Q96DR5](Q96DR5)   BPI fold‐containing family A member 2            11                  41     0.49             S                Immune response, defense                         NI
  [Q14CN2](Q14CN2)   Calcium‐activated chloride channel regulator 4   5                   8      0.23             S                Transport                                        NI
  [P27482](P27482)   Calmodulin‐like protein 3                        6                   64     0.37             S                Metal binding, chaperone                         NI
  [P27797](P27797)   Calreticulin                                     4                   19     0.37             S                Chaperone                                        NI
  [P00915](P00915)   Carbonic anhydrase 1                             6                   34     8.55             S                Metabolic enzyme, acid--base balance             Saliva [22](#feb412391-bib-0022){ref-type="ref"}
  [P00450](P00450)   Ceruloplasmin                                    27                  37     3.65             AS               Metal binding                                    Blood [39](#feb412391-bib-0039){ref-type="ref"}
  [O00299](O00299)   Chloride intracellular channel protein 1         7                   34     0.31             S                Transport, cell cycle regulation                 NI
  [P01024](P01024)   Complement C3                                    84                  61     2.77             AS               Immune response                                  Saliva [36](#feb412391-bib-0036){ref-type="ref"}
  [P0C0L5](P0C0L5)   Complement C4‐B                                  32                  25     6.69             AS               Immune response                                  Saliva [36](#feb412391-bib-0036){ref-type="ref"}
  [P01031](P01031)   Complement C5                                    7                   5      Only in OSCC     AS               Immune response                                  NI
  [B4E1Z4](B4E1Z4)   CFB                                              22                  22     5.44             AS               Immune response                                  Saliva [36](#feb412391-bib-0036){ref-type="ref"}
  [P08603](P08603)   CFH                                              21                  22     Only in OSCC     AS               Immune response                                  NI
  [P05156](P05156)   Complement factor I                              3                   7      6.42             AS               Immune response                                  NI
  [P22528](P22528)   Cornifin‐B                                       6                   79     0.45             S                Cornification                                    NI
  [P08185](P08185)   Corticosteroid‐binding globulin                  4                   15     Only in OSCC     AS               Protease inhibitor                               Saliva [23](#feb412391-bib-0023){ref-type="ref"}
  [P04080](P04080)   Cystatin‐B                                       6                   86     0.39             S                Protease inhibitor                               NI
  [P01034](P01034)   Cystatin‐C                                       7                   43     0.33             S                Protease inhibitor                               NI
  [P09228](P09228)   Cystatin‐SA                                      13                  69     0.35             S                Protease inhibitor                               Saliva [14](#feb412391-bib-0014){ref-type="ref"}
  [P99999](P99999)   Cytochrome *c*                                   4                   32     0.00             A                Electron transport chain, apoptosis              Tissue [53](#feb412391-bib-0053){ref-type="ref"}
  [Q02413](Q02413)   Desmoglein‐1                                     8                   12     0.40             S                Desmosome component                              NI
  [P61916](P61916)   Epididymal secretory protein E1                  4                   33     0.30             S                Lipid metabolism, cholesterol transport          NI
  [Q01469](Q01469)   Fatty acid‐binding protein, epidermal            12                  79     0.49             S                Lipid metabolism                                 Saliva[a](#feb412391-note-0002){ref-type="fn"} [23](#feb412391-bib-0023){ref-type="ref"}
  [P02671](P02671)   Fibrinogen alpha chain                           11                  13     2.67             AS               Blood coagulation                                Blood [40](#feb412391-bib-0040){ref-type="ref"}
  [P02675](P02675)   Fibrinogen beta chain                            20                  49     2.91             AS               Blood coagulation                                Blood [40](#feb412391-bib-0040){ref-type="ref"}
  [P02679](P02679)   Fibrinogen gamma chain                           18                  48     2.43             AS               Blood coagulation                                Blood [40](#feb412391-bib-0040){ref-type="ref"}
  [B7ZLE5](B7ZLE5)   FN1 protein                                      24                  17     5.73             S                Cell adhesion                                    Tissue [42](#feb412391-bib-0042){ref-type="ref"}
  [P00738](P00738)   Haptoglobin                                      29                  67     2.61             AS               Heme binding                                     Blood [38](#feb412391-bib-0038){ref-type="ref"}
  [P69905](P69905)   Hemoglobin subunit alpha                         11                  92     3.37             S                Oxygen transport                                 Saliva[a](#feb412391-note-0002){ref-type="fn"} [23](#feb412391-bib-0023){ref-type="ref"}
  [P68871](P68871)   Hemoglobin subunit beta                          17                  94     4.41             S                Oxygen transport                                 Saliva[a](#feb412391-note-0002){ref-type="fn"} [23](#feb412391-bib-0023){ref-type="ref"}
  [P02790](P02790)   Hemopexin                                        20                  52     2.41             AS               Heme binding                                     Saliva [16](#feb412391-bib-0016){ref-type="ref"}, [22](#feb412391-bib-0022){ref-type="ref"}
  [P05546](P05546)   Heparin cofactor 2                               8                   17     Only in OSCC     A                Blood coagulation                                Saliva [23](#feb412391-bib-0023){ref-type="ref"}
  [Q9Y6R7](Q9Y6R7)   IgGFc‐binding protein                            52                  17     0.49             S                Immune response                                  NI
  [P11215](P11215)   Integrin alpha‐M                                 6                   9      2.01             S                Immune response                                  Tissue [41](#feb412391-bib-0041){ref-type="ref"}
  [P19827](P19827)   Inter‐alpha‐trypsin inhibitor heavy chain H1     8                   14     3.76             S                Protease inhibitor                               Saliva [23](#feb412391-bib-0023){ref-type="ref"}
  [P19823](P19823)   Inter‐alpha‐trypsin inhibitor heavy chain H2     10                  18     11.23            S                Protease inhibitor                               Saliva [23](#feb412391-bib-0023){ref-type="ref"}
  [Q14624](Q14624)   Inter‐alpha‐trypsin inhibitor heavy chain H4     13                  22     5.33             S                Protease inhibitor                               Saliva [23](#feb412391-bib-0023){ref-type="ref"}
  [P02538](P02538)   Keratin, type II cytoskeletal 6A                 21                  39     0.44             S                Cytoskeleton                                     NI
  [P01042](P01042)   Kininogen‐1                                      11                  18     2.89             S                Protease inhibitor, blood coagulation            Saliva [23](#feb412391-bib-0023){ref-type="ref"}
  [P61626](P61626)   Lysozyme C                                       7                   54     0.47             S                Host defense                                     NI
  [P40926](P40926)   Malate dehydrogenase, mitochondrial              4                   17     0.37             S                Metabolic enzyme                                 NI
  [Q8TAX7](Q8TAX7)   Mucin‐7                                          4                   12     0.00             S                Host defense                                     NI
  [P80303](P80303)   Nucleobindin‐2                                   8                   26     0.32             S                Metal binding                                    Saliva [23](#feb412391-bib-0023){ref-type="ref"}
  [Q6UX06](Q6UX06)   Olfactomedin‐4                                   7                   20     0.47             S                Cell adhesion                                    NI
  [P36871](P36871)   Phosphoglucomutase‐1                             6                   13     0.08             S                Metabolic enzyme                                 NI
  [Q96G03](Q96G03)   Phosphoglucomutase‐2                             5                   11     0.40             S                Metabolic enzyme                                 NI
  [P00558](P00558)   Phosphoglycerate kinase 1                        10                  33     0.44             S                Metabolic enzyme                                 Saliva [22](#feb412391-bib-0022){ref-type="ref"}
  [P36955](P36955)   Pigment epithelium‐derived factor                4                   12     7.17             S                Tumor development, angiogenesis                  NI
  [P05155](P05155)   Plasma protease C1 inhibitor                     8                   21     5.95             S                Protease inhibitor, blood coagulation            NI
  [P00747](P00747)   Plasminogen                                      9                   17     5.11             AS               Blood coagulation                                NI
  [P02760](P02760)   Protein AMBP                                     6                   23     5.41             S                Protease inhibitor, host defense                 Saliva [23](#feb412391-bib-0023){ref-type="ref"}
  [O60888](O60888)   Protein CutA                                     3                   33     0.43             S                Metal binding, enzyme binding                    NI
  [P02753](P02753)   Retinol‐binding protein 4                        5                   24     2.54             S                Protease inhibitor, host defense                 Blood [38](#feb412391-bib-0038){ref-type="ref"}
  [Q9NQ38](Q9NQ38)   Serine protease inhibitor Kazal‐type 5           11                  13     0.32             S                Lipid metabolism                                 NI
  [P36952](P36952)   Serpin B5                                        4                   14     2.63             S                Tumor suppressor                                 Blood [12](#feb412391-bib-0012){ref-type="ref"}
  [P02768](P02768)   Serum albumin                                    71                  84     2.53             S                Transport                                        Saliva [22](#feb412391-bib-0022){ref-type="ref"}
  [P27169](P27169)   Serum paraoxonase/arylesterase 1                 9                   37     Only in OSCC     A                Detoxification                                   Saliva [23](#feb412391-bib-0023){ref-type="ref"}
  [P35326](P35326)   Small proline‐rich protein 2A                    6                   79     0.29             S                Cornification                                    Saliva[a](#feb412391-note-0002){ref-type="fn"} [23](#feb412391-bib-0023){ref-type="ref"}
  [Q6UWP8](Q6UWP8)   Suprabasin                                       12                  33     0.05             S                Cell proliferation                               NI
  [P62328](P62328)   Thymosin beta‐4                                  5                   64     0.42             S                Actin binding, cell proliferation                NI
  [O60235](O60235)   Transmembrane protease serine 11D                3                   10     0.20             S                Protease, host defense                           NI
  [P68363](P68363)   Tubulin alpha‐1B chain                           4                   12     0.40             S                Microtubule component                            Saliva[a](#feb412391-note-0002){ref-type="fn"} [23](#feb412391-bib-0023){ref-type="ref"}
  [O75083](O75083)   WD repeat‐containing protein 1                   7                   19     0.13             S                Cell migration                                   NI

Indicates that not the protein itself, but another close family member of it was already found in OSCC.
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Two proteins, cytochrome *c* and mucin‐7, were only present in the CTL samples, and six proteins, complement factor H (CFH) and C5 (C5), corticosteroid‐binding globulin (SERPINA6), heparin cofactor 2 (SERPIND1), apolipoprotein E (APOE), and serum paraoxonase/arylesterase 1 (PON1), were only present in the OSCC samples (Table [3](#feb412391-tbl-0003){ref-type="table-wrap"}).

###### 

Proteins identified only in the OSCC or CTL group

  Protein ID[a](#feb412391-note-0003){ref-type="fn"}   Protein name                       Gene name   Function                                                                      Presence    Reference to previous studies
  ---------------------------------------------------- ---------------------------------- ----------- ----------------------------------------------------------------------------- ----------- ------------------------------------------------------------------------------------------------------------------------------------------
  [P02649](P02649)                                     APOE                               APOE        Lipid metabolism                                                              Only OSCC   Identified in saliva of patients with OSCC [23](#feb412391-bib-0023){ref-type="ref"}
  [P01031](P01031)                                     Complement C5                      C5          Innate immune response, complement component                                  Only OSCC   Not identified in cancer yet
  [P08603](P08603)                                     CFH                                CFH         Innate immune response, complement component                                  Only OSCC   Identified in other forms of cancer but not in OSCC [49](#feb412391-bib-0049){ref-type="ref"}, [50](#feb412391-bib-0050){ref-type="ref"}
  [P08185](P08185)                                     Corticosteroid‐binding globulin    SERPINA6    Protease inhibitor                                                            Only OSCC   Identified in saliva of patients with OSCC [23](#feb412391-bib-0023){ref-type="ref"}
  [P05546](P05546)                                     Heparin cofactor 2                 SERPIND1    Blood coagulation                                                             Only OSCC   Identified in saliva of patients with OSCC [23](#feb412391-bib-0023){ref-type="ref"}
  [P27169](P27169)                                     Serum paraoxonase/arylesterase 1   PON1        Detoxification                                                                Only OSCC   Identified in saliva of patients with OSCC [23](#feb412391-bib-0023){ref-type="ref"}
  [P99999](P99999)                                     Cytochrome *c*                     CYCS        Electron transport chain, its release from mitochondria initiates apoptosis   Only Ctrl   Its release was inhibited in OSCC [53](#feb412391-bib-0053){ref-type="ref"}
  [Q8TAX7](Q8TAX7)                                     Mucin‐7                            MUC7        Antibacterial activity, host defense                                          Only Ctrl   Not identified in cancer yet

Based on <http://www.uniprot.org/>.

John Wiley & Sons, Ltd

Functional analysis of salivary proteins {#feb412391-sec-0012}
----------------------------------------

It was observed that the level of some proteins such as apolipoproteins, components of the complement system, proteinases, proteinase inhibitors, components of the coagulation cascade is upregulated. This might indicate a change in proteolysis most probably associated with the interrelated coagulation cascade‐complement activation processes. At the same time, the level of proteins having role in metabolism and host defense was downregulated showing extensive cancer‐related changes (Table [2](#feb412391-tbl-0002){ref-type="table-wrap"}). For a more detailed functional analysis of the differentially expressed proteins, GO analysis was performed; the Biological Process, Molecular Function, and Cellular Localization according to GO (<http://www.geneontology.org/>) were examined. First, the network of differentially expressed proteins was generated using [string]{.smallcaps} version 10.5 [28](#feb412391-bib-0028){ref-type="ref"}, [29](#feb412391-bib-0029){ref-type="ref"}, followed by GO enrichment analysis provided by String. The network of downregulated proteins contained 35 proteins (nodes) and 27 possible protein--protein interactions analyzed at medium stringency (Fig. [2](#feb412391-fig-0002){ref-type="fig"}A). No biological function was enriched in the downregulated proteins in this loosely connected network (Fig. [2](#feb412391-fig-0002){ref-type="fig"}B); however, seven of 35 downregulated proteins are metabolic enzymes participating mainly in carbohydrate metabolism and 10 of 35 proteins have a role in defense. The upregulated 45 proteins show a highly interconnected protein--protein interaction network with 400 interactions analyzed at medium stringency (Fig. [2](#feb412391-fig-0002){ref-type="fig"}C). The enriched functions indicate active regulatory mechanisms implicating the immune system, lipid metabolism, plasminogen activation, antioxidant activity, and inhibition of enzymatic activities (Fig. [2](#feb412391-fig-0002){ref-type="fig"}D). Regarding localization of up‐ or downregulated proteins, all are mainly extracellular proteins according to GO (Fig. [2](#feb412391-fig-0002){ref-type="fig"}B,D), but a part of the upregulated proteins originate from lipid particles or platelet alpha‐granules indicating the presence of a possibly cancer‐induced complex process involving systemic mechanisms.

![The protein--protein interaction network and functional classification of up‐ and downregulated proteins in OSCC. The network of downregulated (A) and upregulated (C) proteins in OSCC displayed by String 10.4 using default settings and medium stringency. Each node represents a protein and the edges represent protein--protein interactions based on different levels of evidence collected by String. The enrichment table of GO terms calculated by String in the case of downregulated (B) and upregulated (D) proteins is shown indicating the number of the proteins belonging to each term and the false discovery rate calculated by String.](FEB4-8-556-g002){#feb412391-fig-0002}

To obtain more insights into the changes associated with OSCC, a literature search was performed to see which proteins have been associated with oncogenesis. Most of the proteins were already associated with OSCC, and 32 proteins were identified to be present in saliva in this pathological condition.

Complement C4B (C4B), complement factor B (CFB), complement C3, and alpha‐1‐antitrypsin were shown to be associated with the risk of developing OSCC according to a targeted proteomics study [36](#feb412391-bib-0036){ref-type="ref"}. The levels of apolipoproteins A and E; PON1; inter‐alpha‐trypsin inhibitor heavy chain H1, H2, and H4; kininogen 1; protein AMBP; nucleobindin‐2; SERPIND1; and SERPINA6 were found to be upregulated in OSCC in shotgun proteomics experiments carried out on saliva samples [23](#feb412391-bib-0023){ref-type="ref"}. The presence of APOE was related to the increased invasion potential of OSCC [37](#feb412391-bib-0037){ref-type="ref"}.

The alpha‐1‐acid glycoprotein, alpha‐1B glycoprotein, alpha‐amylase, beta‐2‐glycoprotein, carbonic anhydrase 1, cystatin‐SA, hemopexin, phosphoglycerate kinase, and serum albumin were identified as potential salivary markers of OSCC [14](#feb412391-bib-0014){ref-type="ref"}, [16](#feb412391-bib-0016){ref-type="ref"}, [22](#feb412391-bib-0022){ref-type="ref"}.

Some of the proteins found to be differentially expressed in our study, such as fibrinogen alpha, beta, and gamma chains, haptoglobin, SERPINB5, retinol‐binding protein 4, and ceruloplasmin, were shown to be plasma markers of OSCC, while the presence of integrin alpha‐M and fibronectin FN1 was demonstrated in the OSCC tissue [12](#feb412391-bib-0012){ref-type="ref"}, [38](#feb412391-bib-0038){ref-type="ref"}, [39](#feb412391-bib-0039){ref-type="ref"}, [40](#feb412391-bib-0040){ref-type="ref"}, [41](#feb412391-bib-0041){ref-type="ref"}, [42](#feb412391-bib-0042){ref-type="ref"}.

In the case of 36 proteins, no association with OSCC was found so far (Table [2](#feb412391-tbl-0002){ref-type="table-wrap"}). Angiotensinogen and plasminogen themselves were not found to be associated with OSCC, but the plasminogen activator system was shown to be a predictive marker for early OSCC, and by bioinformatics analysis, the angiotensin‐converting enzymes were associated with malignant epithelial neoplasia characteristic of OSCC [43](#feb412391-bib-0043){ref-type="ref"}, [44](#feb412391-bib-0044){ref-type="ref"}. In the case of six proteins, not the protein from our list, but another protein from the same family was already demonstrated to be differentially expressed in OSCC (Table [2](#feb412391-tbl-0002){ref-type="table-wrap"}). In the case of SERPINB5, there are contradictory data; in our study, the level of SERPINB5 was found to be elevated in OSCC; however, the SERPINB5 and different forms of SERPINS from clade B were found by other groups to be downregulated in OSCC on mRNA level and higher SERPINB5 levels were found to correlate with better prognosis of patients with oral cancer [45](#feb412391-bib-0045){ref-type="ref"}, [46](#feb412391-bib-0046){ref-type="ref"}.

Plasma protease C1 inhibitor (SERPING1), antithrombin III, and fibronectin were found to play a role in carcinogenesis, but their implication in oral cancer, especially in OSCC, has not been demonstrated yet [47](#feb412391-bib-0047){ref-type="ref"}, [48](#feb412391-bib-0048){ref-type="ref"}. The CFH was previously identified in lung adenocarcinoma and cutaneous squamous cell carcinoma, but not in OSCC [49](#feb412391-bib-0049){ref-type="ref"}, [50](#feb412391-bib-0050){ref-type="ref"}, and apoB100 was found in serum of patients with head and neck squamous cell carcinoma [51](#feb412391-bib-0051){ref-type="ref"}. No data were found on the presence of complement C5 and mucin‐7 in cancer; however, other components of the complement system and other forms of mucins were all identified in different forms of cancer and in OSCC as well [36](#feb412391-bib-0036){ref-type="ref"}, [52](#feb412391-bib-0052){ref-type="ref"}.

As for the involvement of cytochrome *c*, it was shown that the HIF‐1α‐dependent suppression of hypoxia‐induced apoptosis in OSCC happens through the inhibition of cytochrome *c* release [53](#feb412391-bib-0053){ref-type="ref"}.

Examination of the level of selected proteins by ELISA {#feb412391-sec-0013}
------------------------------------------------------

Many of the studies published in the scientific literature are based on shotgun proteomics experiments. Only few of the proteins listed in Table [2](#feb412391-tbl-0002){ref-type="table-wrap"} were verified or validated either using SRM‐based targeted or antibody‐based methods. Considering the proteins present only in OSCC based on our shotgun experiments, the data presented in the literature, and the availability of antibodies, SERPIND1 and C5 were selected for further studies. To test the utility of potential biomarkers identified in Asia for a European population, resistin reported to be a potential biomarker for OSCC in Taiwan [23](#feb412391-bib-0023){ref-type="ref"} was also selected.

The concentrations of C5, SERPIND1, and resistin were examined in the saliva of patients with OSCC, MCTL, and YCTL using quantitative sandwich ELISA kits (Fig. [3](#feb412391-fig-0003){ref-type="fig"}). In the case of C5, the difference was significant but only when YCTL and patients with OSCC or YCTL and MCTL were compared, indicating that the level of C5 was age‐dependent or it was influenced by other factors. One such factor can be the inflammatory status related to poor oral hygiene often observed in the middle‐aged and elderly population in Hungary [54](#feb412391-bib-0054){ref-type="ref"}. This means that despite the differential expression of C5 in the OSCC group, the level of C5 does not discriminate between the target MCTL and the diseased group, and hence, it cannot be used as a biomarker for OSCC.

![Examination of potential salivary biomarkers using ELISA. The concentration of SERPIND1 (A), resistin (B), and complement C5 (C) proteins in the saliva samples collected from patients with OSCC,YCTL, and MCTL. The *P* value is indicated; \* refers to *P* \< 0.05.](FEB4-8-556-g003){#feb412391-fig-0003}

In the case of resistin and SERPIND1, no significant differences were found between the groups. Resistin was not up‐ or downregulated according to our shotgun experiments and did not show significant differences in the ELISA experiments either. In the case of SERPIND1, one possible explanation of the disagreement between the shotgun proteomics and ELISA data can be that the low number of samples (three for each group) tested by shotgun proteomics and the high individual variation of the saliva samples collected from the patients may lead to false‐positive results. This outcome highlights the importance of validation of the shotgun proteomics data on larger patient cohorts to decrease the false positivity of biomarker identifications. In a two‐stage experimental approach, starting with a shotgun proteomics experiment, the level of resistin was found to be significantly higher in the saliva samples of patients with OSCC compared to controls. However, following ELISAs showed that the median values in the OSCC group were only slightly elevated compared to the control group [23](#feb412391-bib-0023){ref-type="ref"}. In the same study, SERPIND1 was not validated but was shown to be upregulated in the saliva samples of patients with OSCC. In our study, a similar experimental setup was applied; in the shotgun experiment, the level of SERPIND1 was higher but the level of resistin did not change markedly in the OSCC group, and the validation of SERPIND1 and resistin shows that none of them turned to be useful potential biomarkers. The fact that resistin was identified as a biomarker for OSCC in Taiwan but not in Hungary gives further evidence for the importance of regional studies highlighted in our previous work [55](#feb412391-bib-0055){ref-type="ref"}.

Conclusions {#feb412391-sec-0014}
===========

Global analysis of salivary samples from patients with OSCC and controls contributes to the better understanding of the disease, including the interaction of tumor cells with their environment and the influence of cancer lesion on salivary protein ecology. Salivary proteins, characterizing patients with OSCC in this study, highlighted the importance of networks involving the immune system and proteolysis in this disease. Six proteins were only detected in OSCC samples by proteomics analyses and two of them were further examined using ELISA, but none of the proteins turned to be a potential biomarker in OSCC in our study group. The fact that resistin was shown to be a possible biomarker in Taiwan but not in our study highlights the importance of regional or population‐tailored studies.

Author contributions {#feb412391-sec-0016}
====================

IM, EC, and CK designed the experiments; IM and JN performed stomatologic examination of patients; BM and ZD carried out the experiments; BM, ZD, and EC evaluated the data and wrote the manuscript; BM, ES, and EC prepared the figures and tables; and JT, KM, CK, and IM reviewed the manuscript.

Supporting information
======================

###### 

**Table S1**. List of identified proteins.

###### 

Click here for additional data file.

###### 

 

###### 

Click here for additional data file.

This work was supported by the János Bolyai Research Scholarship of the Hungarian Academy of Sciences, Hungarian Scientific Research Fund OTKA K105034; TÁMOP‐4.2.2.D‐15/1/KONV‐2015‐0016 project implemented through the New Széchenyi Plan cofinanced by the European Social Fund; and the National Research, Development and Innovation Office \[GINOP‐2.3.2‐15‐2016‐00020 and GINOP‐2.3.2‐15‐2016‐00001\]. The work of Kamilla Sólyom and Jánosné Tóth is greatly acknowledged.

[^1]: Equally contributing first authors.
